Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × TP protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 4 Uterine Cervical Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor Cancer 1 Recurrence 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 101 Dexamethasone 54 Cytarabine 47 fludarabine phosphate 45 fludarabine 44 Rituximab 44 Gemcitabine 34 Peripheral Blood Stem Cell Transplantation 32 Lenalidomide 32 Etoposide 32 pembrolizumab 30 Radiotherapy 29 Filgrastim 29 Busulfan 28 Cyclosporine 26 Methotrexate 25 Melphalan 25 Carboplatin 25 Cisplatin 24 venetoclax 23 Mycophenolic Acid 23 Paclitaxel 22 Bortezomib 22 Whole-Body Irradiation 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Antilymphocyte Serum 19 Temozolomide 18 Oxaliplatin 17 Decitabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01405235 2012-04-12

AGO-Zervix-1

Institut fuer Frauengesundheit

Phase 3 Unknown

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡